Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shenzhen - Delayed Quote CNY

Kunming Longjin Pharmaceutical Co., Ltd. (002750.SZ)

1.1300
0.0000
(0.00%)
At close: April 24 at 3:04:54 PM GMT+8
Loading Chart for 002750.SZ
  • Previous Close 1.1300
  • Open 1.1800
  • Bid --
  • Ask 1.1300 x --
  • Day's Range 1.1300 - 1.1600
  • 52 Week Range 1.1300 - 5.0400
  • Volume 11,644,640
  • Avg. Volume 9,871,262
  • Market Cap (intraday) 452.565M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date May 23, 2018
  • 1y Target Est --

Kunming Longjin Pharmaceutical Co., Ltd. therapeutic medicines for people living with cardiovascular, cerebrovascular, and metabolic diseases in China. The company offers medicines in the areas of cardiovascular and cerebrovascular, digestive system, vitamin, minerals and enteral nutrition, and immunology, as well as first aid kits; extracts of natural plants, such as breviscapine; and industrial hemp consumer products. It also engages in the industrial hemp plantation business. Kunming Longjin Pharmaceutical Co., Ltd. was founded in 1996 and is headquartered in Kunming, China.

www.longjin.com.cn

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 002750.SZ

View More

Performance Overview: 002750.SZ

Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

002750.SZ
48.40%
SSE Composite Index (000001.SS)
0.27%

1-Year Return

002750.SZ
78.68%
SSE Composite Index (000001.SS)
6.19%

3-Year Return

002750.SZ
91.57%
SSE Composite Index (000001.SS)
11.36%

5-Year Return

002750.SZ
87.69%
SSE Composite Index (000001.SS)
16.41%

Compare To: 002750.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 002750.SZ

View More

Valuation Measures

Annual
As of 5/6/2025
  • Market Cap

    452.56M

  • Enterprise Value

    184.84M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.83

  • Price/Book (mrq)

    0.97

  • Enterprise Value/Revenue

    4.02

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -62.34%

  • Return on Assets (ttm)

    -2.99%

  • Return on Equity (ttm)

    -9.07%

  • Revenue (ttm)

    66.48M

  • Net Income Avi to Common (ttm)

    -41.44M

  • Diluted EPS (ttm)

    -0.1000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    295.16M

  • Total Debt/Equity (mrq)

    0.75%

  • Levered Free Cash Flow (ttm)

    -8.16M

Research Analysis: 002750.SZ

View More

Company Insights: 002750.SZ

Research Reports: 002750.SZ

View More

People Also Watch